Herceptin(R)(trastuzumab); Kadcyla(R)(trastuzumab emtansine);
Polivy(R)(polatuzumab vedotin); Tarceva(R)(erlotinib);
Venclexta(R)/Venclyxto(R)(venetoclax) in collaboration with AbbVie;
Xeloda(R)(capecitabine); Zelboraf(R)(vemurafenib). Furthermore, the
Roche Group has a robust investigational oncology pipeline focusing on
new therapeutic targets and novel combination strategies. For more
information on Roche's approach to cancer, visit
Roche is a global pioneer in pharmaceuticals and diagnostics focused on
advancing science to improve people's lives. The combined strengths of
pharmaceuticals and diagnostics under one roof have made Roche the
leader in personalised healthcare -- a strategy that aims to fit the
right treatment to each patient in the best way possible.
Roche is the world's largest biotech company, with truly differentiated
medicines in oncology, immunology, infectious diseases, ophthalmology
and diseases of the central nervous system. Roche is also the world
leader in in vitro diagnostics and tissue-based cancer diagnostics, and
a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent,
diagnose and treat diseases and make a sustainable contribution to
society. The company also aims to improve patient access to medical
innovations by working with all relevant stakeholders. More than thirty
medicines developed by Roche are included in the World Health
Organization Model Lists of Essential Medicines, among them life-saving
antibiotics, antimalarials and cancer medicines. Moreover, for the
twelfth consecutive year, Roche has been recognised as one of the most
sustainable companies in the Pharmaceuticals Industry by the Dow Jones
Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over
100 countries and in 2020 employed more than 100,000 people worldwide.
In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF
58.3 billion. Genentech, in the United States, is a wholly owned member
of the Roche Group. Roche is the majority shareholder in Chugai
Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org
Dr. Nicolas Dunant Patrick Barth
Phone: +41 61 687 05 17 Phone: +41 61 688 44 86
Dr. Daniel Grotzky Karsten Kleine
Phone: +41 61 688 31 10 Phone: +41 61 682 28 31
Nina Mählitz Nathalie Meetz
Phone: +41 79 327 54 74 Phone: +41 61 687 43 05
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
-- 11052021_MR_ASCO 2021 Curtain Raiser
(END) Dow Jones Newswires
May 11, 2021 01:00 ET (05:00 GMT)